Treatment of High-Risk Neuroblastoma

被引：12
作者：
Krystal, Julie [1 ]
Foster, Jennifer H. [2 ]
机构：
[1] Cohen Childrens Med Ctr, Zucker Hofstra Sch Med, Dept Pediat, New Hyde Pk, NY 11040 USA
[2] Texas Childrens Canc Ctr, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
来源：
CHILDREN-BASEL | 2023年 / 10卷 / 08期
关键词：
neuroblastoma; pediatric oncology; solid tumor; OPEN-LABEL; CLASSIFICATION-SYSTEM; PROGNOSTIC IMPACT; CHILDHOOD-CANCER; FREE SURVIVAL; LOCAL-CONTROL; COG A3973; PHASE-II; CHILDREN; CHEMOTHERAPY;
D O I：
10.3390/children10081302
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
High-risk neuroblastoma is a highly aggressive solid tumor that most commonly presents in early childhood. Advances in treatment through decades of clinical trials and research have led to improved outcomes. This review provides an overview of the current state of treatment for high-risk neuroblastoma.
引用
收藏
页数：11
相关论文
共 50 条
  • [31] Upfront Treatment of High-Risk Neuroblastoma With a Combination of 131I-MIBG and Topotecan
    Kraal, Kathelijne C. J. M.
    Tytgat, Godelieve A. M.
    van Eck-Smit, Berthe L. F.
    Kam, Boen
    Caron, Huib N.
    van Noesel, Max
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 1886 - 1891
  • [32] Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed
    Ceci, Adriana
    Conte, Rosa
    Didio, Antonella
    Landi, Annalisa
    Ruggieri, Lucia
    Giannuzzi, Viviana
    Bonifazi, Fedele
    FRONTIERS IN MEDICINE, 2023, 10
  • [33] Value of surgical resection in children with high-risk neuroblastoma
    Englum, Brian R.
    Rialon, Kristy L.
    Speicher, Paul J.
    Gulack, Brian
    Driscoll, Timothy A.
    Kreissman, Susan G.
    Rice, Henry E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (09) : 1529 - 1535
  • [34] Venous Thrombosis and Procoagulant Factors in High-risk Neuroblastoma
    Schiavetti, Amalia
    Foco, Micaela
    Chiriaco, Damiano
    Iacobini, Metello
    Varrasso, Giulia
    Ingrosso, Annapaola
    Conti, Laura
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (02) : 93 - 96
  • [35] MELK is a novel therapeutic target in high-risk neuroblastoma
    Guan, Shan
    Lu, Jiaxiong
    Zhao, Yanling
    Yu, Yang
    Li, Hui
    Chen, Zhenghu
    Shi, Zhongcheng
    Liang, Haoqian
    Wang, Mopei
    Guo, Kevin
    Chen, Xiangmei
    Sun, Wenjing
    Bieerkehazhi, Shayahati
    Xu, Xin
    Sun, Surong
    Agarwal, Saurabh
    Yang, Jianhua
    ONCOTARGET, 2018, 9 (02) : 2591 - 2602
  • [36] Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification
    Berthold, Frank
    Ernst, Angela
    Ackermann, Sandra
    Bartenhagen, Christoph
    Christiansen, Holger
    Hero, Barbara
    Rosswog, Carolina
    von Schweinitz, Dietrich
    Klingebiel, Thomas
    Schmid, Irene
    Simon, Thorsten
    Fischer, Matthias
    CANCERS, 2021, 13 (17)
  • [37] Timing and chemotherapy association for 131-I-MIBG treatment in high-risk neuroblastoma
    Mastrangelo, Stefano
    Romano, Alberto
    Attina, Giorgio
    Maurizi, Palma
    Ruggiero, Antonio
    BIOCHEMICAL PHARMACOLOGY, 2023, 216
  • [38] Retrospective analysis of relapsed abdominal high-risk neuroblastoma
    Duebbers, Martin
    Simon, Thorsten
    Berthold, Frank
    Fischer, Janina
    Volland, Ruth
    Hero, Barbara
    Cernaianu, Grigore
    JOURNAL OF PEDIATRIC SURGERY, 2018, 53 (03) : 558 - 566
  • [39] Dinutuximab: A Review in High-Risk Neuroblastoma
    Sheridan M. Hoy
    Targeted Oncology, 2016, 11 : 247 - 253
  • [40] Retinoid therapy of high-risk neuroblastoma
    Reynolds, CP
    Matthay, KK
    Villablanca, JG
    Maurer, BJ
    CANCER LETTERS, 2003, 197 (1-2) : 185 - 192
12345